ACM
JBIO

ADAR1 Capital Management’s Jade Biosciences JBIO Stock Holding History

ADAR1 Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,000
Closed -$281K – 286
2026
Q1 		$281K Sell
20,000
-1,000
-5% -$14.5K 0.02% 243
2025
Q4 		$324K Buy
+21,000
New +$246K 0.02% 208
2025
Q2 		– Sell
-41,750
Closed -$3.67M – 212
2025
Q1 		$3.67M Buy
41,750
+15,235
+57% +$1.34M 0.68% 42
2024
Q4 		$2.46M Buy
26,515
+23,284
+721% +$2.01M 0.49% 44
2024
Q3 		$236K Sell
3,231
-3,824
-54% -$247K 0.04% 154
2024
Q2 		$410K Buy
7,055
+6,601
+1,454% +$4.38M 0.08% 108
2024
Q1 		$470K Buy
+454
New +$347K 0.11% 86

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ADAR1 Capital Management's JBIO Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Jade Biosciences (JBIO) in Q2 2026, closing a stake of 20,000 shares — an estimated $281K sold.

ADAR1 Capital Management first reported a position in JBIO in Q1 2024 and held it in 7 quarters. The position peaked at $3.67M in Q1 2025. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Jade Biosciences position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 20,000 Jade Biosciences shares in Q2 2026, an estimated $281K.
  • ADAR1 Capital Management first reported a position in Jade Biosciences in Q1 2024 and held it in 7 quarters.
  • ADAR1 Capital Management's Jade Biosciences position peaked at $3.67M in Q1 2025.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.